

Genome-wide Association Study of Obsessive-Compulsive Disorder

Abstract

Obsessive-compulsive disorder (OCD) is a common, debilitating neuropsychiatric illness with complex genetic etiology. The International OCD Foundation Genetics Collaborative (IOCDF-GC) is a multi-national collaboration established to discover the genetic variation predisposing to OCD. A set of individuals affected with DSM-IV OCD, a subset of their parents, and unselected controls, were genotyped with several different Illumina SNP microarrays. After extensive data cleaning, 1,465 cases, 5,557 ancestry-matched controls and 400 complete trios remained, with a common set of 469,410 autosomal and 9,657 X-chromosome SNPs. Ancestry-stratified case-control association analyses were conducted for three genetically-defined subpopulations and combined in two meta-analyses, with and without the trio-based analysis. In the case-control analysis, the lowest two p-values were located within *DLGAP1* ($p=2.49 \times 10^{-6}$ and $p=3.44 \times 10^{-6}$), a member of the neuronal postsynaptic density complex. In the trio analysis, rs6131295, near *BTBD3*, exceeded the genome-wide significance threshold with a $p\text{-value}=3.84 \times 10^{-8}$. However, when trios were meta-analyzed with the combined case-control samples, the p-value for this variant was 3.62×10^{-5} , losing genome-wide significance. Although no SNPs were identified to be associated with OCD at a genome-wide significant level in the combined trio-case-control sample, a significant enrichment of methylation-QTLs ($p<0.001$) and frontal lobe eQTLs ($p=0.001$) was observed within the top-ranked SNPs ($p<0.01$) from the trio-case-control analysis, suggesting these top signals may have a broad role in gene expression in the brain, and possibly in the etiology of OCD.

Introduction

Obsessive-compulsive disorder (OCD) is a neuropsychiatric disorder characterized by obsessions and/or compulsions that are distressing, time consuming or significantly impairing.

OCD is the fourth most common psychiatric illness¹ with a lifetime prevalence of 1-3%.^{2, 3} OCD was identified as the anxiety disorder with the highest proportion (50.6%) of serious cases by the National Comorbidity Study Replication⁴ and as a leading global cause of non-fatal illness burden by the World Health Organization (WHO) in 2006.⁵

Genetic studies have demonstrated that both biological and environmental factors are important in the etiology of OCD. A multitude of OCD family studies published since the 1930's provide strong evidence for an approximate four to ten-fold OCD risk increase among first-degree relatives of OCD-affected children and adults, respectively, as compared to relatives of controls.⁶⁻¹⁴ A review of twin studies concluded that obsessive-compulsive (OC) symptoms are heritable, with greater genetic influences in child-onset (45-65%), than in adult-onset OCD cases (27- 48%).¹⁵ This finding has been supported by subsequent twin studies¹⁶⁻¹⁸. Linkage study results have been somewhat encouraging,¹⁹ identifying peaks on chromosomes 3q,²⁰ 9p,²¹ 10p,^{22, 23} 15q^{20, 24} and 19q¹⁹ for OCD and on chromosome 14 for compulsive hoarding.²⁵ Unfortunately, none of these peaks exceeded the threshold for genome-wide significance, and only one the 9p peak has reached suggestive significance in more than one sample.¹⁹⁻²¹

In addition, more than 80 positional and functional candidate gene studies of OCD have been reported, predominantly for variants within genes in the serotonin, dopamine and glutamate^{26,27} pathways and those involved in immune and white matter pathways.²⁸ *SLC1A1*, which encodes a neuronal glutamate transporter and which is within the linkage peak on chromosome 9p, is the only candidate gene observed to be associated in multiple independent samples, although the specific associated variant has varied.²⁹⁻³²

Excessive grooming and anxiety-like behaviors have been observed in mice lacking expression of *SAPAP3*, a post-synaptic scaffolding protein located at excitatory synapses. This finding,

coupled with high *SAPAP3* expression levels in the striatum, identify its human ortholog (*DLGAP3*) as an appealing candidate gene in OCD.³³ Human studies have provided some support for a possible role of *DLGAP3* in OCD-related disorders, suggesting increased rare non-synonymous variant frequencies in OCD/trichotillomania subjects³⁴ and association of common *DLGAP3* variants with pathologic grooming in a family-based study,³⁵ albeit with some inconsistencies.³⁶

In recent years, the genome-wide association study (GWAS) approach has led to the identification of many genetic associations for common complex traits.³⁷ This model-free approach to gene discovery has led to a greater pathophysiologic understanding of many disorders, although only small proportions of the total genetic variance have so far been explained, and many of the identified variants have not brought new biological understanding.³⁸ To address the latter concern, functional support for GWAS findings has been sought by determining their effects on gene expression (expression quantitative trait loci- eQTLs) and methylation level (methylation quantitative trait loci-mQTLs).³⁸ Top single nucleotide polymorphisms (SNPs) have also been examined for potential enrichment of eQTLs and mQTLs, compared to expected rates. Moreover, examination for over-representation of micro-RNA (miRNA) binding sites has also been adopted as an informative approach,³⁹ given the role of miRNA in regulating gene expression. In addition, pathway analyses have been conducted to determine whether specific gene pathways are enriched among the strongest associated variants.⁴⁰

The International OCD Foundation Genetic Collaborative (IOCDF-GC), consisting of more than 20 research groups, has performed a GWAS to search for common SNPs predisposing to OCD. We present our findings from an analysis of the genetic association between OCD and a genome-wide set of common SNPs among case-control and trio samples and their combined

trio-case-control results. We also present analyses of top GWAS findings with respect to their biological function in OCD-related and other brain regions.

Materials and Methods

Subjects and Genotyping

Our initial sample consisted of 1,817 DSM-IV⁴¹ OCD cases, 504 controls and 663 complete trios, genotyped using the Illumina Human610-Quadv1_B SNP array. This work was approved by the relevant IRBs at all participating sites, and all participants provided written informed consent. The majority of the control subjects genotyped as a part of this project were not screened for the absence of OCD. We also used data from 5,654 unscreened controls, previously genotyped on two different Illumina SNP arrays (Table S1).

Quality Control

The data for this study underwent QC and data cleaning with a concurrent GWAS of Tourette Syndrome (Scharf et al., *Molecular Psychiatry*, submitted),⁴⁶ using PLINK,⁴⁷ to exclude samples and SNPs for each array type (Figure S1).

Statistical analyses

To control for Type I error due to residual population stratification, case and control samples were separated into subpopulations of European (EU), South African Afrikaner (SA) and Ashkenazi Jewish (AJ) ancestry, using Multi-Dimensional Scaling (MDS) analysis (Supplementary Figures S2-4). Population stratification outliers and those lacking genomically-matched controls or cases were excluded, as were samples with excessive low-level relatedness to many others within each subpopulation. Separate association analyses were conducted for each of the case-control subsamples (EU, SA and AJ) and for the trio samples. For the former, logistic regression was employed using an additive test model (1 df), with

diagnostic status as the dependent variable and each single SNP as the predictor, including specific ancestry-informative MDS axes as covariates (EU= 4 factors, SA= 2 factors, and AJ=1 factor). For the latter, the Transmission Disequilibrium Test (TDT) was used.

Two meta-analyses were conducted using METAL⁴⁸ by combining the three case-control sub-populations, and by combining the three case-control subgroups and the trio group, weighting by the number of cases or trios (Supplementary materials). Each SNP was tested separately, defining a genome-wide significance threshold at $p < 5 \times 10^{-8}$, based on a 5% Type I error rate.³⁷ Using the PLINK retrieval interface,⁴⁷ SNP annotations were created using the TAMAL database⁴⁹ based chiefly on UCSC genome browser files,⁵⁰ HapMap⁵¹ and dbSNP.⁵² Further annotation was conducted using SCAN⁵³ and SPOT⁵⁴ and top SNPs ($p < 0.001$) were also manually annotated using the UCSC genome browser.⁵⁵ For analysis of sex chromosome SNPs, males and females were assessed separately for each subgroup, with adjustment by MDS factors as described above, and subsequent combination via meta-analysis, using the number of cases or trios as a weighting factor. A sign test was conducted to examine for increased consistent directionality of effect for the most strongly associated SNPs between the case-control and trio samples. Analyses of potential enrichment of SNPs from: a) 22 previously identified candidate genes, b) pre-defined gene pathways, and c) target gene intervals containing micro-RNA (miRNA) binding sites⁵⁶, among the top hits from the case-control, trio, or trio-case-control trio-case-control GWAS results were performed using INRICH.⁴⁰

eQTL and mQTL annotation and enrichment tests

Functional support for the SNPs with the strongest evidence of association in the trio-case-control meta-analysis was sought by determining effects of the most significantly associated SNPs ($p < 0.001$) on both gene expression (expression quantitative trait loci- eQTLs) and on methylation level (methylation quantitative trait loci-mQTLs). This was done with eQTLs from

frontal lobes,⁵⁷ parietal lobes,⁵⁷ lymphoblastoid cell lines (LCL),⁵⁸ and the cerebellum,⁵⁸ and with mQTLs⁵⁸ from cerebellum, using previously collected data.⁵⁸ To test whether the SNPs with the strongest observed associations were enriched for eQTLs or mQTLs, the LD-independent SNPs from the trio-case-control analyses with $p < 0.001$ and with $p < 0.01$ were compared to 1,000 random sets of the same size, conditioning on allele frequency, to yield an empirical distribution. An enrichment p-value was then calculated as the proportion of randomized sets in which the eQTL (or mQTL) count matched or exceeded the actual observed count in the list of top SNP associations, as previously described⁵⁷ (see Supplementary materials).

Imputation of SNPs

Imputation of SNPs was conducted proximal to any SNPs with genome-wide significance from the trio, combined case-control or trio-case-control samples. This was completed using the 1000 Genomes Project via IMPUTE2,⁵⁹ and haplotypes from the 1,092 individuals in a 1000 Genomes Data Release⁶⁰ as a reference dataset. Post-imputation QC and allelic dosage analysis were conducted in PLINK (see Supplementary materials).

Results

Multidimensional scaling analyses identified three distinct genetic subpopulations within the case-control sample, which corresponded to: European (EU), South African (SA) and Ashkenazi Jewish (AJ) ancestries (Supplementary materials). After QC, a total of 1,465 cases (1,279 EU, 93 SA and 93 AJ), 5,557 controls (5,139 EU, 260 AJ and 158 SA) and 400 complete trios (299 EU) remained and each had genotypes for a common set of 469,410 autosomal and 9,657 X-chromosome SNPs (Table S1). Quantile-quantile (QQ) plots of the observed versus expected $\log(p)$ values under the null hypothesis were used to calculate genomic control lambda values for the trio ($\lambda = 1.015$), case-control ($\lambda = 1.002$), and trio-case-control samples

($\lambda=1.011$) (Figure 1). QQ plots for EU ($\lambda=1.009$), SA ($\lambda=0.969$) and AJ ($\lambda=0.982$) case-control subpopulations were also constructed (Supplementary Figure S7). There was no evidence for significant residual stratification effects in any of the comparisons.

Trio Sample Results

An overview of the p-values for the trio analysis plotted against genomic location is illustrated in Figure 2a. Of the top 4 OCD-associated SNPs in the trio sample with p-values $< 1 \times 10^{-5}$, one SNP, rs6131295 (11,996,267bp (hg19) on 20p12.1-2), exceeded the threshold for genome-wide significance of $p < 5 \times 10^{-8}$ with a $p = 3.84 \times 10^{-8}$.⁶¹ This SNP is located ~90 kb 3' to *BTBD3* (Figure 3). None of the other 442 SNPs with p-values < 0.001 were in LD ($r^2 > 0.2$) with this SNP (Supplementary Table S2).

Case-Control Sample Results

In the case-control sample, no SNPs exceeded the genome-wide threshold for significance (Table 1, Figure 2). Nine OCD-associated SNPs had p-values $< 1 \times 10^{-5}$ (Table 1). The lowest two p-values were for SNPs rs11081062 ($p = 2.49 \times 10^{-6}$) and rs11663827 ($p = 3.44 \times 10^{-6}$), located at chromosome 18 within an intron of *DLGAP1* (Figure 3). *DLGAP1* (also known as *SAPAP1*) encodes the discs, large (Drosophila) homolog-associated protein a member of the neuronal postsynaptic density complex. The third lowest p-value was for the SNP rs26728 ($p = 4.75 \times 10^{-6}$), located within an intron of *EFNA5*, encoding Ephrin-A5 (Supplementary Figure S12). Ephrins are important for development of the neocortex through regulation of axonal inhibition or repulsion,⁶² and *EFNA5* was also among top hits in an Alzheimer's disease GWAS.⁶³ The fourth lowest p-value $= 5.40 \times 10^{-6}$, was for rs4868342, lying within an intron of *HMP19*, encoding the brain-specific HMP19 protein (Supplementary Figure S12), which is expressed in the Golgi complex.⁶⁴ The fifth lowest p-value $= 5.81 \times 10^{-6}$, was for rs297941, which is located

approximately 21 kb 5' to the gene encoding *FAIM2* (also known as *LFG*) and about 25 kb from a cluster of genes encoding a group of aquaporins (*AQP5*, *AQP6*, *AQP2*), and lies within a putative coding region of mRNA BC034605, isolated from testis (Supplementary Figure S12).

Trio-Case-Control Meta-Analysis Results

None of the SNPs exceeded the genome-wide threshold for significance, although several of the top hits were also identified among top hits in either the trio analysis or in the case-control analysis (Figure S12). Using the sign test with 3616 LD-pruned SNPs with $p < 0.01$, there was evidence for increased consistent directionality ($1907/3616 = 0.52$; $p = 5.25 \times 10^{-4}$ for 1-sided binomial test) between the trios and the combined case-controls. The top 38 OCD-associated SNPs in this meta-analysis, with p -values $< 5 \times 10^{-5}$, are presented in Table 1. For example, the top signal ($p = 4.99 \times 10^{-7}$), rs297941 near *FAIM2*, was also the fifth ranked SNP in the case-control analysis. *FAIM2* is highly expressed in the central nervous system and plays a role in Fas-mediated cell death.⁶⁵ When rs6131295 (the SNP with significant genome-wide association in the trio sample) was meta-analyzed along with the case-control sample, the combined p -value increased to 3.62×10^{-5} .

Examination of prior OCD linkage regions and candidate genes

There was no evidence found for genome-wide significant association with OCD in either previously identified putative linkage regions (Supplementary Table S3) or in 22 previously identified candidate genes when examining the trio, case-control and trio-case-control groups. The Q-Q plot of candidate gene SNPs for the combined case-control group shows little inflation ($\lambda = 1.085$, Supplementary Figure S8), suggesting no evidence for over-representation within these genes. While the Q-Q plot of the combined trio-case-control sample indicates small inflation ($\lambda = 1.168$, Supplementary Figure S8), the follow-up enrichment test demonstrated no

over-representation of top hits ($p < 0.001$ and $p < 0.01$) within previously identified candidate genes ($p = 0.15$ and $p = 0.10$, respectively). For the 22 OCD candidate genes examined, the lowest SNP p -values are reported in Supplementary Table S4. The strongest finding was observed for *ADARB2*²², with a p -value = 1.6×10^{-4} , which did not survive correction for multiple testing of candidate gene SNPs (corrected $p = 0.53$).

eQTL and mQTL annotation and enrichment analyses

Support for the SNPs with the strongest evidence of association in the combined trio-case-control sample was sought by determining functional effects of the most significantly associated autosomal SNPs. These top SNPs were annotated with expression QTL (eQTLs) data from frontal, parietal and cerebellar brain regions (Table 1), along with lymphoblastoid cell lines (LCLs) (Supplementary Table S2) and methylation levels (mQTLs) in cerebellum (Table 1).

SNPs with association p -values < 0.01 ($n = 3,521$) were then examined for enrichment of eQTLs and mQTLs. Significant enrichment was observed for frontal eQTLs ($p = 0.001$) as well as for cerebellar eQTLs ($p = 0.033$) and parietal eQTLs ($p = 0.003$) (Figure 4a-c). Furthermore, enrichment of cerebellar mQTLs was observed ($p < 0.001$) with an enrichment p -value of $p < 0.001$ (Figure 4d), suggesting that these SNPs are more likely to influence the methylation state. No significant enrichment for either genic ($p = 0.54$) or missense variants (0.34) was observed. A similar analysis examining only the top SNPs with association p -values < 0.001 ($n = 415$) demonstrated no significant enrichment for mQTLs or for eQTLs ($p > 0.05$).

miRNA and pathway analyses

After correction for multiple hypothesis testing, there was no evidence for enrichment of specific miRNA binding sites among the LD-blocks containing top SNPs compared to the genes

matched with size and marker density (see Supplementary Table S5). The strongest enrichment was found in 49 high-confidence (TargetScan probability>0.9) predicted miRNA-219-5p/508/508-3p/4782-3p targets, two of which have at least one SNP with $p<0.001$ (empirical $p=0.011$, corrected $p=0.060$) in the case-control GWAS result. A similar level of enrichment was also found in 89 high-confidence predicted miR-130ac/301ab/301b/301b-3p/454/721/4295/3666 targets, two of which have at least one SNP with $p<0.001$ in trio TDT result. In the pathway analyses, no results achieved significance at the corrected p-value (lowest corrected $p=0.55$) (see Supplementary Table S6).

Discussion

We report results from the first genome-wide association study (GWAS) to search for common DNA sequence variation predisposing individuals to OCD. After removing low performing SNP assays and DNA samples, we analyzed 400 trios, 1,465 cases and 5,557 controls for 469,410 autosomal and 9,657 X-chromosome SNPs. The trio and case-control subsamples were analyzed individually, and then these results were combined in both case-control and trio-case-control meta-analyses. One SNP, rs6131295, located on chromosome 20p12.1-p12.2, approximately ~90 kb from the *BTBD3* gene, was genome-wide significant in the trio analysis ($p=3.84\times 10^{-8}$), but not in the combined case-control and trio meta-analysis, suggesting that further examination will be required using independent samples. *BTBD3* is a member of a large family of transcription factors, which includes *BTBD9*, a gene that has been associated with Tourette Syndrome, a disorder frequently co-morbid with OCD.⁶⁶ *BTBD3* participates in multiple cellular functions including transcriptional regulation, cytoskeleton dynamics, ion channel assembly and gating, protein ubiquitination and degradation⁶⁷ and has also been associated with primary open-angle glaucoma.⁶⁸ *BTBD3* is expressed in the brain, with the highest observed levels in childhood and adolescence (www.BrainSpan.org, Release 3),⁶⁷ when OCD

frequently emerges.⁶⁹ rs6131295 is a cis-eQTL for *BTBD3* in the frontal cortex (p=0.028), a region that has repeatedly been implicated in OCD. This SNP is also a parietal cis-eQTL for *ISM1* (20p12;p=0.0036) and an LCL trans-eQTL for *DHRS11* (17q11.2;p=0.0001).

Interestingly, the brain-wide expression pattern of *DHRS11* and *ISM1* are highly correlated with the expression of several of the other genes found among the top hits of both the case-control and the trio-case-control meta-analyses (www.BrainSpan.org, Release 3) (Supplementary Figure S12).⁷⁰ Furthermore, many of these genes have been implicated in glutamate signaling. Specifically, *ISM1* (*C20orf82*) is correlated with expression of pre-synaptically-located *ADCY8* (0.61, rank 11 of 22,328 transcripts), the gene with the seventh strongest OCD-association in the trio-case-control meta-analysis, which has also been associated with bipolar disorder⁷¹ and with fear memory.⁷² *ISM1* is also correlated with brain-wide expression of numerous glutamate-related genes including *GRIK4* (0.565, rank 66), *DLGAP3* (0.576,rank 44), *GRIK1* (0.595,rank 22), *SHANK3* (0.598,rank 21) as well as *ADARB2* (0.600,rank 19), which contains the SNP with the best p-value in this study among previously reported candidate genes (Supplementary Table S4), and lies within a childhood-onset OCD linkage peak.²² Similarly, the expression of *DHRS11* (*MGC4172*) is strongly correlated (0.847, rank 25 of 22,328 transcripts) with that of *FAIM2*, which is located in the same LD block as the best SNP (rs297941) in the trio-case-control, and fifth best in the case-control meta-analyses. *FAIM2* has been associated with neuroprotection following transient brain ischemia.⁷² The rat homologue of *FAIM2*, neural membrane protein 35 (*NMP35*), is expressed at the post-synaptic membrane in a subset of synapses and in dendrites, and co-localizes with the glutamate receptor *GluR2*.⁶⁵ Thus, there is a potential relationship between rs6131295 (trio analysis), and *FAIM2* and *ADCY8* (tagged by the SNPs ranked #1 and #7 in the trio-case-control analysis).

The top two SNPs associated in the case-control meta-analysis (both with $p < 3 \times 10^{-5}$ in the trio-case-control meta-analysis) are located in *DLGAP1*, another gene which influences glutamate signaling. *DLGAP1* encodes a Shank-associated protein and has been associated with schizophrenia and with a smoking cessation phenotype⁷³ and three *DLGAP1* deletions have also been observed (2 in schizophrenia cases and 1 in controls).⁷⁴ Another member of this gene family, *DLGAP3*, has been implicated in compulsive-like behavior in a mouse model (*SAPAP3*). Specifically, knockout mice for the striatum-expressed *SAPAP3* gene (which codes for a post-synaptic protein at cortico-striatal glutamatergic excitatory synapses) developed repetitive grooming behaviors and anxiety that were reversed with an SSRI and with gene replacement.²⁴

Several of the top associations in the combined trio-case-control meta-analysis are in or near genes that have been implicated in other studies of psychiatric disorders, including *ADCY8*^{63, 75, 76}, *ARHGAP18*⁴⁷ and *JMJD2C*⁶² in bipolar disorder, schizophrenia and autism spectrum disorders, respectively. Enrichment for eQTLs was observed among the top associated GWAS SNPs ($N=5,321$; $p < 0.01$), with empirical p-values of 0.001 for frontal cortex, 0.003 for parietal tissue and 0.033 for cerebellum. Marked enrichment was also observed for methylation QTLs ($p < 0.001$). This is consistent with the finding by Nicolae et al. (2010),⁵⁸ who reported that disease-associated SNPs from GWAS were significantly more likely to be eQTLs, than other random sets of SNPs with similar minor-allele-frequencies (MAF).

It remains unclear whether the finding at rs6131295, which exceeded genome-wide significance with $p=3.84 \times 10^{-8}$ in the trio sample, is a false positive or not. Certainly the decrease in significance of the p-value to 3.62×10^{-5} when the trio data is meta-analyzed with the much larger case-control sample data suggests so. On the other hand, our attempts to determine whether this finding was spurious did not find any evidence of such, as detailed here: 1) The intensity

plot for this SNP has three tight, separated, clusters (Figure S10a); 2) There were no missing genotypes in the trio sample and there were no Mendelian errors; 3) Two nearby directly genotyped SNPs with low r^2 values (0.2-0.4) had p-values within the 10^{-2} range, demonstrating very low statistical significance (Figure S10b); and 4) Imputation of the trio sample provided additional results that are not inconsistent with a true positive finding. Of the 40 regional SNPs examined, those with large r^2 values (>0.90) and similar minor allele frequencies to rs6131295 had strong p-values in the range of 10^{-6} and 10^{-7} (Table S7 and Figure S11). Moreover, the surrounding SNPs in low r^2 with rs6131295 all have an opposite direction of risk effect, which may partially explain why they have much less significant p-values. Although these imputed data and the above noted facts cannot prove that rs6131295 is a true positive, they do not support the hypothesis that it is a false positive. Replication with additional samples will be required to provide further clarification.

In summary, although no SNPs were identified to be associated with OCD at a genome-wide significant level in the combined trio-case-control sample, a highly significant enrichment of methylation-QTLs ($p < 0.001$) and frontal lobe eQTLs ($p = 0.001$) was observed within the top-ranked SNPs ($p < 0.01$). This suggests that these top signals may have a broad role in gene expression in the brain, and possibly in the etiology of OCD. In the trio sample, we observed a genome-wide significant result for rs6131295, which is located near *BTBD3*, and is an eQTL for *BTBD3*, *DHRS11* and *ISM1*. The expression of these latter two genes are highly correlated with other top hits, many of which are related to glutamatergic neurotransmission and signaling. So, while no genome-wide significant associations were found in the entire sample, the convergence of results from both the trio and combined trio-case-control analyses suggest the possibility that our findings at *BTBD3*, *FAIM2* and *ADCY8* are genes involved in the pathogenesis of OCD. In the case-control sample, the two most significant p-values were located within *DLGAP1*, a member of the same gene family as *DLGAP3*, which is also

expressed in the neuronal postsynaptic density complex and which has been implicated in a mouse model of OCD,³³ making these results intriguing. Future exploration and attempts to replicate these findings with additional independent samples is warranted.

References

1. Kaplan HI, Sadock BJ. *Study guide and self-examination review for Kaplan and Sadock's synopsis of psychiatry*. 6th edn. Williams & Wilkins: Baltimore, 1998, 541pp.
2. Karno M, Golding JM, Sorenson SB, Burnam MA. The epidemiology of obsessive-compulsive disorder in five US communities. *Arch Gen Psychiatry* 1988; **45**(12): 1094-1099.
3. Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National Comorbidity Survey Replication. *Mol Psychiatry* 2010; **15**(1): 53-63.
4. Blazer DG, Kessler RC, McGonagle KA, Swartz MS. The prevalence and distribution of major depression in a national community sample: the National Comorbidity Survey. *Am J Psychiatry* 1994; **151**(7): 979-986.
5. Ayuso-Mateos J. Global Burden of obsessive-compulsive disorder in the year 2000. World Health Organization, 2006.
6. Luxenburger H. Hereditat und Familientypus der Zwangsneurotiker. *Archives of Psychiatry* 1930; **91**: 590-594.
7. Lewis A. Problems of obsessional illness. *Proceedings of the Royal Society of Medicine* 1935; **29**: 325-336.
8. Brown FW. Heredity in the Psychoneuroses (Summary). *Proc R Soc Med* 1942; **35**(12): 785-790.
9. Rudin E. [On the problem of compulsive disease with special reference to its hereditary relations]. *Arch Psychiatr Nervenkr Z Gesamte Neurol Psychiatr* 1953; **191**(1): 14-54.
10. Kringlen E. Obsessional Neurotics: A Long-Term Follow-up. *Br J Psychiatry* 1965; **111**: 709-722.
11. Rosenberg CM. Familial aspects of obsessional neurosis. *Br J Psychiatry* 1967; **113**(497): 405-413.
12. Carey G, Goldsmith H, Tellegen A, Gottesman I. Genetics and personality inventories: The limits of replication with twin data. *Behaviour Genetics* 1978; **8**(4): 299-313.
13. Insel TR, Hoover C, Murphy DL. Parents of patients with obsessive-compulsive disorder. *Psychol Med* 1983; **13**(4): 807-811.
14. Rasmussen SA, Tsuang MT. Clinical characteristics and family history in DSM-III obsessive-compulsive disorder. *Am J Psychiatry* 1986; **143**(3): 317-322.
15. van Grootheest DS, Cath DC, Beekman AT, Boomsma DI. Twin studies on obsessive-compulsive disorder: a review. *Twin Res Hum Genet* 2005; **8**(5): 450-458.

16. Iervolino AC, Rijsdijk FV, Cherkas L, Fullana MA, Mataix-Cols D. A multivariate twin study of obsessive-compulsive symptom dimensions. *Arch Gen Psychiatry* 2011; **68**(6): 637-644.
17. Moore J, Smith GW, Shevlin M, O'Neill FA. Alternative factor models and heritability of the Short Leyton Obsessional Inventory-Children's Version. *J Abnorm Child Psychol* 2010; **38**(7): 921-934.
18. Bolton D, Rijsdijk F, Eley TC, O'Connor TG, Briskman J, Perrin S. Normative childhood repetitive routines and obsessive compulsive symptomatology in 6-year-old twins. *J Child Psychol Psychiatry* 2009; **50**(9): 1139-1146.
19. Hanna GL, Veenstra-VanderWeele J, Cox NJ, Boehnke M, Himle JA, Curtis GC *et al.* Genome-wide linkage analysis of families with obsessive-compulsive disorder ascertained through pediatric probands. *Am J Med Genet* 2002; **114**(5): 541-552.
20. Shugart YY, Samuels J, Willour VL, Grados MA, Greenberg BD, Knowles JA *et al.* Genomewide linkage scan for obsessive-compulsive disorder: evidence for susceptibility loci on chromosomes 3q, 7p, 1q, 15q, and 6q. *Mol Psychiatry* 2006; **11**(8): 763-770.
21. Willour VL, Yao Shugart Y, Samuels J, Grados M, Cullen B, Bienvenu OJ *et al.* Replication study supports evidence for linkage to 9p24 in obsessive-compulsive disorder. *Am J Hum Genet* 2004; **75**(3): 508-513.
22. Hanna GL, Veenstra-Vanderweele J, Cox NJ, Van Etten M, Fischer DJ, Himle JA *et al.* Evidence for a susceptibility locus on chromosome 10p15 in early-onset obsessive-compulsive disorder. *Biol Psychiatry* 2007; **62**(8): 856-862.
23. Liang KY, Wang Y, Shugart YY, Grados M, Fyer AJ, Rauch S *et al.* Evidence for potential relationship between SLC1A1 and a putative genetic linkage region on chromosome 14q to obsessive-compulsive disorder with compulsive hoarding. *Am J Med Genet B Neuropsychiatr Genet* 2008; **147B**(6): 1000-1002.
24. Ross J, Badner J, Garrido H, Sheppard B, Chavira DA, Grados M *et al.* Genomewide linkage analysis in Costa Rican families implicates chromosome 15q14 as a candidate region for OCD. *Hum Genet* 2011.
25. Samuels J, Shugart YY, Grados MA, Willour VL, Bienvenu OJ, Greenberg BD *et al.* Significant linkage to compulsive hoarding on chromosome 14 in families with obsessive-compulsive disorder: results from the OCD Collaborative Genetics Study. *Am J Psychiatry* 2007; **164**(3): 493-499.
26. Pittenger C, Bloch MH, Williams K. Glutamate abnormalities in obsessive compulsive disorder: Neurobiology, pathophysiology, and treatment. *Pharmacol Ther* 2011; **132**(3): 314-332.
27. Wu K, Hanna GL, Rosenberg DR, Arnold PD. The role of glutamate signaling in the pathogenesis and treatment of obsessive-compulsive disorder. *Pharmacol Biochem Behav* 2011.

28. Stewart SE, Platko J, Fagerness J, Birns J, Jenike E, Smoller JW *et al.* A genetic family-based association study of OLIG2 in obsessive-compulsive disorder. *Arch Gen Psychiatry* 2007; **64**(2): 209-214.
29. Stewart SE, Fagerness JA, Platko J, Smoller JW, Scharf JM, Illmann C *et al.* Association of the SLC1A1 glutamate transporter gene and obsessive-compulsive disorder. *Am J Med Genet B Neuropsychiatr Genet* 2007; **144B**(8): 1027-1033.
30. Arnold PD, Sicard T, Burroughs E, Richter MA, Kennedy JL. Glutamate transporter gene SLC1A1 associated with obsessive-compulsive disorder. *Arch Gen Psychiatry* 2006; **63**(7): 769-776.
31. Dickel DE, Veenstra-VanderWeele J, Cox NJ, Wu X, Fischer DJ, Van Etten-Lee M *et al.* Association testing of the positional and functional candidate gene SLC1A1/EAAC1 in early-onset obsessive-compulsive disorder. *Arch Gen Psychiatry* 2006; **63**(7): 778-785.
32. Wendland JR, Moya PR, Timpano KR, Anavitarte AP, Kruse MR, Wheaton MG *et al.* A haplotype containing quantitative trait loci for SLC1A1 gene expression and its association with obsessive-compulsive disorder. *Arch Gen Psychiatry* 2009; **66**(4): 408-416.
33. Welch JM, Lu J, Rodriguiz RM, Trotta NC, Peca J, Ding JD *et al.* Cortico-striatal synaptic defects and OCD-like behaviours in Sapap3-mutant mice. *Nature* 2007; **448**(7156): 894-900.
34. Züchner S, Wendland JR, Ashley-Koch AE, Collins AL, Tran-Viet KN, Quinn K *et al.* Multiple rare SAPAP3 missense variants in trichotillomania and OCD. *Mol Psychiatry* 2009; **14**(1): 6-9.
35. Bienvenu OJ, Wang Y, Shugart YY, Welch JM, Grados MA, Fyer AJ *et al.* Sapap3 and pathological grooming in humans: Results from the OCD collaborative genetics study. *Am J Med Genet B Neuropsychiatr Genet* 2009; **150B**(5): 710-720.
36. Boardman L, van der Merwe L, Lochner C, Kinnear CJ, Seedat S, Stein DJ *et al.* Investigating SAPAP3 variants in the etiology of obsessive-compulsive disorder and trichotillomania in the South African white population. *Compr Psychiatry* 2011; **52**(2): 181-187.
37. Cichon S, Craddock N, Daly M, Faraone SV, Gejman PV, Kelsoe J *et al.* Genomewide association studies: history, rationale, and prospects for psychiatric disorders. *Am J Psychiatry* 2009; **166**(5): 540-556.
38. Gamazon ER, Huang RS, Cox NJ, Dolan ME. Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. *Proc Natl Acad Sci U S A* 2010; **107**(20): 9287-9292.
39. Ripke S, Sanders AR, Kendler KS, Levinson DF, Sklar P, Holmans PA *et al.* Genome-wide association study identifies five new schizophrenia loci. *Nat Genet* 2011; **43**(10): 969-976.

40. Lee PH, O'Dushlaine C, Thomas B, Purcell SM. INRICH: Interval-based Enrichment Analysis for Genome Wide Association Studies. *Bioinformatics* 2012.
41. American Psychiatric Association. *Diagnostic criteria from DSM-IV-TR*. American Psychiatric Association: Washington, D.C., 2000, xii, 370 p.pp.
42. Bierut LJ, Saccone NL, Rice JP, Goate A, Foroud T, Edenberg H *et al*. Defining alcohol-related phenotypes in humans. The Collaborative Study on the Genetics of Alcoholism. *Alcohol Res Health* 2002; **26**(3): 208-213.
43. Bierut LJ, Madden PA, Breslau N, Johnson EO, Hatsukami D, Pomerleau OF *et al*. Novel genes identified in a high-density genome wide association study for nicotine dependence. *Hum Mol Genet* 2007; **16**(1): 24-35.
44. Bierut LJ, Strickland JR, Thompson JR, Afful SE, Cottler LB. Drug use and dependence in cocaine dependent subjects, community-based individuals, and their siblings. *Drug Alcohol Depend* 2008; **95**(1-2): 14-22.
45. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D *et al*. Common variants conferring risk of schizophrenia. *Nature* 2009; **460**(7256): 744-747.
46. Scharf JM, Mathews CA. Copy number variation in Tourette syndrome: another case of neurodevelopmental generalist genes? *Neurology* 2010; **74**(20): 1564-1565.
47. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D *et al*. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 2007; **81**(3): 559-575.
48. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide association scans. *Bioinformatics* 2010; **26**(17): 2190-2191.
49. Hemminger BM, Saelim B, Sullivan PF. TAMAL: an integrated approach to choosing SNPs for genetic studies of human complex traits. *Bioinformatics* 2006; **22**(5): 626-627.
50. Hinrichs AS, Karolchik D, Baertsch R, Barber GP, Bejerano G, Clawson H *et al*. The UCSC Genome Browser Database: update 2006. *Nucleic Acids Res* 2006; **34**(Database issue): D590-598.
51. The International HapMap C. A haplotype map of the human genome. *Nature* 2005; **437**(7063): 1299-1320.
52. Wheeler DL, Barrett T, Benson DA, Bryant SH, Canese K, Chetvermin V *et al*. Database resources of the National Center for Biotechnology Information. *Nucleic Acids Res* 2007; **35**(Database issue): D5-12.
53. Gamazon ER, Zhang W, Konkashbaev A, Duan S, Kistner EO, Nicolae DL *et al*. SCAN: SNP and copy number annotation. *Bioinformatics* 2010; **26**(2): 259-262.
54. Saccone SF, Saccone NL, Swan GE, Madden PA, Goate AM, Rice JP *et al*. Systematic biological prioritization after a genome-wide association study: an application to nicotine dependence. *Bioinformatics* 2008; **24**(16): 1805-1811.

55. Kent WJ, Sugnet CW, Furey TS, Roskin KM, Pringle TH, Zahler AM *et al.* The human genome browser at UCSC. *Genome Res* 2002; **12**(6): 996-1006.
56. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. *Cell* 2005; **120**(1): 15-20.
57. Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, Cox NJ. Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. *PLoS Genet* 2010; **6**(4): e1000888.
58. Gibbs JR, van der Brug MP, Hernandez DG, Traynor BJ, Nalls MA, Lai SL *et al.* Abundant quantitative trait loci exist for DNA methylation and gene expression in human brain. *PLoS Genet* 2010; **6**(5): e1000952.
59. Howie BN, Donnelly P, Marchini J. A flexible and accurate genotype imputation method for the next generation of genome-wide association studies. *PLoS Genet* 2009; **5**(6): e1000529.
60. Consortium GP. A map of human genome variation from population-scale sequencing. *Nature* 2010; **467**(7319): 1061-1073.
61. Dudbridge F, Gusnanto A. Estimation of significance thresholds for genomewide association scans. *Genet Epidemiol* 2008; **32**(3): 227-234.
62. Torii M, Hashimoto-Torii K, Levitt P, Rakic P. Integration of neuronal clones in the radial cortical columns by EphA and ephrin-A signalling. *Nature* 2009; **461**(7263): 524-528.
63. Potkin SG, Turner JA, Fallon JA, Lakatos A, Keator DB, Guffanti G *et al.* Gene discovery through imaging genetics: identification of two novel genes associated with schizophrenia. *Mol Psychiatry* 2009; **14**(4): 416-428.
64. Sabéran-Djoneidi D, Marey-Semper I, Picart R, Studler JM, Tougard C, Glowinski J *et al.* A 19-kDa protein belonging to a new family is expressed in the Golgi apparatus of neural cells. *J Biol Chem* 1995; **270**(4): 1888-1893.
65. Schweitzer B, Suter U, Taylor V. Neural membrane protein 35/Lifeguard is localized at postsynaptic sites and in dendrites. *Brain Res Mol Brain Res* 2002; **107**(1): 47-56.
66. Rivière JB, Xiong L, Levchenko A, St-Onge J, Gaspar C, Dion Y *et al.* Association of intronic variants of the BTBD9 gene with Tourette syndrome. *Arch Neurol* 2009; **66**(10): 1267-1272.
67. Perez-Torrado R, Yamada D, Defossez PA. Born to bind: the BTB protein-protein interaction domain. *Bioessays* 2006; **28**(12): 1194-1202.
68. Sud A, Del Bono EA, Haines JL, Wiggs JL. Fine mapping of the GLC1K juvenile primary open-angle glaucoma locus and exclusion of candidate genes. *Mol Vis* 2008; **14**: 1319-1326.

69. Stewart SE, Rosario MC, Brown TA, Carter AS, Leckman JF, Sukhodolsky D *et al.* Principal components analysis of obsessive-compulsive disorder symptoms in children and adolescents. *Biol Psychiatry* 2007; **61**(3): 285-291.
70. NIMH Transcriptional Atlas of Human Brain Development. www.developinghumanbrain.org, 2011, Date Accessed 2011.
71. Zhang P, Xiang N, Chen Y, Sliwerska E, McInnis MG, Burmeister M *et al.* Family-based association analysis to finemap bipolar linkage peak on chromosome 8q24 using 2,500 genotyped SNPs and 15,000 imputed SNPs. *Bipolar Disord* 2010; **12**(8): 786-792.
72. Wiczorek L, Maas JW, Jr., Muglia LM, Vogt SK, Muglia LJ. Temporal and regional regulation of gene expression by calcium-stimulated adenylyl cyclase activity during fear memory. *PLoS One* 2010; **5**(10): e13385.
73. Rose JE, Behm FM, Drgon T, Johnson C, Uhl GR. Personalized smoking cessation: interactions between nicotine dose, dependence and quit-success genotype score. *Mol Med* 2010; **16**(7-8): 247-253.
74. Kirov G, Pocklington AJ, Holmans P, Ivanov D, Ikeda M, Ruderfer D *et al.* De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. *Mol Psychiatry* 2012; **17**(2): 142-153.
75. de Mooij-van Malsen AJ, van Lith HA, Oppelaar H, Hendriks J, de Wit M, Kostrzewa E *et al.* Interspecies trait genetics reveals association of *Adcy8* with mouse avoidance behavior and a human mood disorder. *Biol Psychiatry* 2009; **66**(12): 1123-1130.
76. Kantojärvi K, Onkamo P, Vanhala R, Alen R, Hedman M, Sajantila A *et al.* Analysis of 9p24 and 11p12-13 regions in autism spectrum disorders: rs1340513 in the *JMJD2C* gene is associated with ASDs in Finnish sample. *Psychiatr Genet* 2010; **20**(3): 102-108.

Table 1: Strongest Associated GWAS Variants in Trio, Case-Control and Combined Trio-Case-Control Samples Single nucleotide polymorphisms (SNP) listed by rs# include those with association P-values $<10^{-5}$ for the trio and case-control samples, and those with P-values $<10^{-4}$ for the combined trio-case-control sample association results. The chromosome (Chr) and base pair location for each SNP are listed in columns to the right of the SNP column. SNPs are listed separately for the analyses of trios (top section of table, with box around results), case-control samples including combined EU, SA and AJ MDS-defined ancestry subgroups (middle section and box), and for combined trio-case-control samples (lower section and box). SNPs with $p < 10^{-3}$ for any of the following are available in online Supplementary Table S2: EU, AJ and SA case-control subgroups individually and combined, trios, and combined case-control-trios). OR indicates the odds ratio for the tested allele in the trio sample. Direction indicates whether the direction of association between OCD and the A1 allele is either positive (+) or negative (-) A1 allele for individual subgroups within the combined (EU, AJ, SA, trios) samples. The left gene and right gene columns lists the closest genes in the SNP region, either being within the gene (no distance given) or right and left flanking genes (+ distance in kilobases) or downstream (- distance in kilobases). For SNPs located within genes, other functional elements in the region are as noted. QTL (eQTL) columns list genes whose expression or methylation levels (m) are associated (P-value) with the specified SNP in that row, specifically as identified previously in EU-ancestry frontal (F), parietal (P) or cerebellar (C) tissue. mQTL and F eQTL data is unavailable for X chromosome SNP.

Figure 1: Quantile-quantile (QQ) Plots of Observed versus Expected $-\log(p)$ Statistics for: (a) Trio samples, (b) Case-Control samples and, (c) Combined Trio-Case-Control Samples. Quantile-quantile plot of observed vs. expected test statistics from the study samples. The 95% confidence interval of expected values is indicated in grey. Corresponding genomic control λ values are indicated within each plot.

Figure 2: Manhattan Plots for: (a) Trio, (b) Case-Control and, (c) Combined Trio-Case-Control Samples. Manhattan plot of all genotyped SNPs from the study samples. Red and blue lines indicate significance thresholds of 5×10^{-8} and 1×10^{-5} , respectively.

Figure 3: Locus Plots for SNPs rs6131295 (near *BTBD3*), rs11081062 (within *DLGAP1*) and rs297941 (near *FAIM2*). Regional association plots of the best supported SNPs from the a) Trio, b) Case-Control (3meta) and c) Trio-Case-Control (4meta) analyses. Locations and observed $-\log(p)$ -values for genotyped SNPs are shown with black squares. LD, in r^2 , to the lowest p-value SNP in each plot is indicated using red shading (white-low LD, red-high LD). Blue lines indicate the estimated recombination rate from HapMap release 22.

Figure 4: Enrichment analyses for Quantitative Trait Loci (QTLs) among GWAS Variants with $p < 0.01$. Enrichment of (a) frontal lobe expression QTLs ($p=0.001$), (b) cerebellum expression QTLs ($p=0.033$), (c) parietal expression QTLs ($p=0.003$), and (d) methylation QTLs ($p < 0.001$) among GWAS SNPs with $p < 0.01$ ($N=5321$). Distribution of the count of QTLs in 1,000 simulations, each matching the MAF distribution of the OCD-associated SNPs. The black dot identifies the observed eQTL or mQTL count in the OCD susceptibility-associated SNPs.